Earnings results for Nektar Therapeutics (NASDAQ:NKTR)
Nektar Therapeutics is expected* to report earnings on 05/06/2021 after market close. The report will be for the fiscal Quarter ending Mar 2021. According to Zacks Investment Research, based on 7 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.74. The reported EPS for the same quarter last year was $-0.53.
Nektar Therapeutics last posted its quarterly earnings data on February 25th, 2021. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.03. The company earned $23.46 million during the quarter, compared to the consensus estimate of $19.64 million. Nektar Therapeutics has generated ($2.52) earnings per share over the last year. Nektar Therapeutics has confirmed that its next quarterly earnings report will be published on Thursday, May 6th, 2021. Nektar Therapeutics will be holding an earnings conference call on Thursday, May 6th. Interested parties can register for or listen to the call using this link.
Analyst Opinion on Nektar Therapeutics (NASDAQ:NKTR)
8 Wall Street analysts have issued ratings and price targets for Nektar Therapeutics in the last 12 months. Their average twelve-month price target is $25.29, predicting that the stock has a possible upside of 34.50%. The high price target for NKTR is $35.00 and the low price target for NKTR is $18.00. There are currently 1 sell rating, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of “Hold.”
Nektar Therapeutics has received a consensus rating of Hold. The company’s average rating score is 2.00, and is based on 1 buy rating, 6 hold ratings, and 1 sell rating. According to analysts’ consensus price target of $25.29, Nektar Therapeutics has a forecasted upside of 34.5% from its current price of $18.80. Nektar Therapeutics has only been the subject of 2 research reports in the past 90 days.
Dividend Strength: Nektar Therapeutics (NASDAQ:NKTR)
Nektar Therapeutics does not currently pay a dividend. Nektar Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: Nektar Therapeutics (NASDAQ:NKTR)
In the past three months, Nektar Therapeutics insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $151,840.00 in company stock. Only 2.99% of the stock of Nektar Therapeutics is held by insiders. 95.32% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Nektar Therapeutics (NASDAQ:NKTR
Earnings for Nektar Therapeutics are expected to decrease in the coming year, from ($2.20) to ($2.51) per share. The P/E ratio of Nektar Therapeutics is -7.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Nektar Therapeutics is -7.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Nektar Therapeutics has a P/B Ratio of 2.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
More latest stories: here